title: Designer natriuretic peptides: a vision for the future of heart failure therapeutics.
abstract: Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create "designer" chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.
authors.affiliation: Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Departments of Medicine and Physiology, Mayo Clinic College of Medicine, 200 First Street S.W, Rochester, MN 55906, USA.
authors.forename: Rosita
authors.initials: R
authors.lastname: Zakeri
authors.forename: John C
authors.initials: JC
authors.lastname: Burnett
mesh_terms: D000818:Animals; D015198:Designer Drugs / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D045265:Natriuretic Peptides / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D015198:Designer Drugs; D045265:Natriuretic Peptides